Company Encyclopedia
View More
name
Progyny
PGNY.US
Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. The company offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. It also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services. In addition, the company offers assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services.
453.12 B
PGNY.USMarket value -Rank by Market Cap -/-

Financial Score

27/12/2025 Update
B
Managed Health CareIndustry
Industry Ranking6/9
Industry medianB
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE11.37%B
    • Profit Margin4.46%C
    • Gross Margin23.24%D
  • Growth ScoreB
    • Revenue YoY11.41%B
    • Net Profit YoY-1.23%C
    • Total Assets YoY20.49%A
    • Net Assets YoY28.77%A
  • Cash ScoreB
    • Cash Flow Margin2242.81%A
    • OCF YoY11.41%B
  • Operating ScoreA
    • Turnover1.74A
  • Debt ScoreB
    • Gearing Ratio29.58%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Leadership Reshuffle Without a Successor Might Change The Case For Investing In Progyny (PGNY)

    Progyny, Inc. announced that President Michael Sturmer will leave by December 31, 2025, without appointing a successor. The expanded C-suite will absorb his responsibilities. This decision may affect Progyny's investment narrative, focusing on leadership cohesion amid growth or margin pressures. The company authorized $200 million in share repurchases, signaling confidence in its model despite structural risks. Progyny projects $1.6 billion revenue and $112.9 million earnings by 2028, requiring 8.9% yearly growth. Investors should consider diverse viewpoints on Progyny's fair value, ranging from $21 to $71.

    Simplywall·
    US
    PGNY
    +1.14%
    Simplywall·
    US
    PGNY
    +1.14%

    Wall Street Zen Downgrades Progyny (NASDAQ:PGNY) to Hold

    Wall Street Zen downgraded Progyny (NASDAQ:PGNY) from a "buy" to a "hold" rating. Other analysts have mixed ratings, with KeyCorp upgrading to "overweight" and Canaccord Genuity maintaining a "hold." Progyny's stock opened at $26.63, with a market cap of $2.30 billion. Recent insider transactions include CEO Peter Anevski buying shares and CFO Mark S. Livingston selling shares. Institutional investors have adjusted their stakes in the company.

    Market Beat·
    US
    PGNY
    +1.14%
    Market Beat·
    US
    PGNY
    +1.14%

    Progyny President’s Employment to End December 2025

    Progyny, Inc. announced that its President, Michael Sturmer, will end his employment on December 31, 2025, but will continue as a consultant until December 31, 2026. The company will not appoint a successor, citing a strengthened executive team. Analysts rate PGNY stock as a Buy with a $28 target, noting strong financial performance and strategic growth initiatives. Progyny specializes in fertility and family-building benefits solutions.

    Tip Ranks·
    US
    PGNY
    +1.14%
    Tip Ranks·
    US
    PGNY
    +1.14%

    Progyny Inc. Awards $250,000 Annual Advisory Fee to Outgoing President Under New Consulting Agreement

    Progyny Inc. announced that President Michael Sturmer will end his employment on December 31, 2025. He will receive severance payments and benefits as per his employment agreement. Sturmer will also serve as a non-employee consultant through December 31, 2026, for an annual advisory fee of $250,000. His vested stock options will remain exercisable if he continues in this role through June 30, 2026.

    Reuters·
    US
    PGNY
    +1.14%
    Reuters·
    US
    PGNY
    +1.14%

    Progyny CFO Mark S. Livingston Reports Sale of Common Shares

    Mark S. Livingston, CFO of Progyny Inc., reported the sale of common shares of the company. This information was published via EDGAR by Progyny Inc. on December 15, 2025. The news is generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    PGNY
    +1.14%
    Reuters·
    US
    PGNY
    +1.14%
    © 2025 Longbridge｜Disclaimer